However, more head‐to‐head comparisons of assays measuring different phospho‐forms of tau, using identical methods, are needed to reach a conclusion on which of these biomarkers most robustly separate AD from non‐AD neurodegenerative dementias. The gene discussed is MAPT; the disease is Alzheimer disease.